RxDoctor Payments Data

Leigh Nadler, MD

Colon & Rectal Surgery · Pittsburgh, PANPI 1780604280

Payments from drug & device makers

What this record shows

The money is spread across several categories — education (40.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 76.6% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $2,715 and has fallen 91.9% since, to $219 in 2025.

$6,229in general payments, 2019–2025

Across 86 payments — averaging $72.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • Braintree Laboratories, Inc.$465
  • Davol Inc.$197
  • Johnson & Johnson$173
  • Pacira Pharmaceuticals Incorporated$103
  • THD America, Inc.$77
  • plus $446 from 11 others

What the payments were for

  • Travel & lodging$1,17819%
  • Food & beverage$2,17435%
  • Education$2,50040%
  • Gifts$3776%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,229 in reported general payments places this provider in the 75th percentile of 108 colon & rectal surgery providers in Pennsylvania.

See all colon & rectal surgery providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$125,086
Medicare patients
217
Services billed
703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide40$26,049
SutabSod Sulf/Pot Chloride/Mag Sulf20$3,055
ErythromycinErythromycin Base52$2,538
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine24$521
Oxycodone Hcl96$422
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip14$341
Neomycin Sulfate65$329
Hydrocortisone43$278
Procto-Med HcHydrocortisone21$253
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav37$244
Ondansetron OdtOndansetron18$191
Ondansetron Hcl58$106
Metronidazole21$98
Pantoprazole Sodium16$66
Famotidine14$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Braintree Laboratories, Inc.Sutab$465$3,05520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 108 colon & rectal surgery providers in Pennsylvania.

Other colon & rectal surgery in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →